SCHEDULE 13G/A 0000902664-24-005221 0001595082 XXXXXXXX LIVE 1 Common Stock, par value $0.001 06/30/2025 0001580063 BIORA THERAPEUTICS, INC. 74319F404 4330 LA JOLLA VILLAGE DRIVE SUITE 200 SAN DIEGO CA 92122 Rule 13d-1(c) M.H. Davidson & Co. b NY 0.00 25624.00 0.00 25624.00 25624.00 N 0.56 PN Includes 24,033 shares of Common Stock issuable upon conversion of notes. As more fully described in Item 4, the reported securities are subject to a 9.90% blocker. The number of shares of Common Stock in rows (6), (8) and (9) and the percentage in row (11) reflect the conversion in full of the notes reported on this cover page, however, the ability to convert such securities at any given time is subject to the 9.90% Blocker which applies to the beneficial ownership of the Reporting Persons in the aggregate. Davidson Kempner Arbitrage, Equities and Relative Value LP b E9 0.00 880603.00 0.00 880603.00 880603.00 N 9.90 PN Includes 827,144 shares of Common Stock issuable upon conversion of notes. As more fully described in Item 4, the reported securities are subject to a 9.90% blocker and the percentage set forth in row (11) gives effect to such blocker. However, rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the conversion in full of the reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9). Davidson Kempner Capital Management LP b DE 0.00 906227.00 0.00 906227.00 906227.00 N 9.90 PN Includes 851,177 shares of Common Stock issuable upon conversion of notes. As more fully described in Item 4, the reported securities are subject to a 9.90% blocker and the percentage set forth in row (11) gives effect to such blocker. However, rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the conversion in full of the reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9). Anthony A. Yoseloff b X1 0.00 906227.00 0.00 906227.00 906227.00 N 9.90 IN Includes 851,177 shares of Common Stock issuable upon conversion of notes. As more fully described in Item 4, the reported securities are subject to a 9.90% blocker and the percentage set forth in row (11) gives effect to such blocker. However, rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the conversion in full of the reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9). BIORA THERAPEUTICS, INC. 4330 La Jolla Village Drive, Suite 300, San Diego, California 92122 This statement is filed by each of the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons": (i) M.H. Davidson & Co., a New York limited partnership ("CO"). M.H. Davidson & Co. GP, L.L.C., a Delaware limited liability company ("CO GP"), is the general partner of CO and Davidson Kempner Liquid GP Topco LLC, a Delaware limited liability company, is the managing member of CO GP. DKCM (as defined below) is responsible for the voting and investment decisions of CO; (ii) Davidson Kempner Arbitrage, Equities and Relative Value LP, a Cayman Islands exempted limited partnership ("DKAERV"). Davidson Kempner Multi-Strategy GP II LLC, a Delaware limited liability company ("DKAERV GP"), is the general partner of DKAERV and Davidson Kempner Liquid GP Topco LLC, a Delaware limited liability company, is the managing member of DKAERV GP. DKCM is responsible for the voting and investment decisions of DKAERV; (iii) Davidson Kempner Capital Management LP, a Delaware limited partnership and a registered investment adviser with the U.S. Securities and Exchange Commission, acts as investment manager to each of CO and DKAERV ("DKCM"). DKCM GP LLC, a Delaware limited liability company, is the general partner of DKCM. The managing members of DKCM are Anthony A. Yoseloff, Conor Bastable, Shulamit Leviant, Morgan P. Blackwell, Patrick W. Dennis, Gabriel T. Schwartz, Zachary Z. Altschuler, Joshua D. Morris, Suzanne K. Gibbons, Gregory S. Feldman, Melanie Levine and James Li;; and (iv) Anthony A. Yoseloff, through DKCM, is responsible for the voting and investment decisions relating to the Common Stock, par value $0.001 ("Common Stock") of Biora Therapeutics, Inc. (the "Company") held by CO and DKAERV reported herein. The address of the principal business office of each of the Reporting Persons is c/o Davidson Kempner Capital Management LP, 9 West 57th Street, 29th Floor, New York, NY 10019. (i) CO - a New York limited partnership (ii) DKAERV - a Cayman Islands exempted limited partnership (iii) DKCM - a Delaware limited partnership (iv) Anthony A. Yoseloff - United States Y The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in this Schedule 13G are calculated based upon an aggregate of 4,552,702 shares of Common Stock outstanding as of November 6, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 filed with the Securities and Exchange Commission on November 14, 2025, and assumes the conversion of the reported notes subject to the 9.90% Blocker (as defined below). Pursuant to the terms of the reported notes, the Reporting Persons cannot convert any of such securities if the Reporting Persons would beneficially own, after any such conversion, more than 9.90% of the outstanding shares of Common Stock (the "9.90% Blocker") and the percentage set forth in Row (11) of the cover page for each Reporting Person give effect to the 9.90% Blocker. Consequently, as of June 30, 2025, the Reporting Persons were not able to convert all of such securities due to the 9.90% Blocker. 9.90% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. M.H. Davidson & Co. /s/ Anthony A. Yoseloff 08/04/2025 Davidson Kempner Arbitrage, Equities and Relative Value LP /s/ Anthony A. Yoseloff 08/04/2025 Davidson Kempner Capital Management LP /s/ Anthony A. Yoseloff 08/04/2025 Anthony A. Yoseloff /s/ Anthony A. Yoseloff 08/04/2025